Tag: big pharma

NIH scientists made $710M in royalties from drug makers — a fact they tried to hide

During the pandemic, the American people started to feel that Big Government was very cozy with Big Pharma.

Now we know just how close they were.

New data from the National Institutes of Health reveal the agency and its scientists collected $710 million in royalties during the pandemic, from late 2021 through 2023. These are payments made by private companies, like pharmaceuticals, to license medical innovations from government scientists.

Almost all that cash — $690 million — went to the National Institute of Allergy and Infectious Diseases, the subagency led by Dr. Anthony Fauci, and 260 of its scientists.

Information about this vast private royalty complex is tightly held by the National Institutes of Health (NIH). My organization, OpenTheBooks.com, was forced to sue to uncover the royalties paid from September 2009 to October 2021, which amounted to $325 million over 56,000 transactions.

Keep reading

Moderna Shares Rise On Report US Gov’t Preparing Funding For mRNA Bird Flu Vax

Shares of Moderna are up more than 4% in the New York premarket trading session following a report by the Financial Times that the US government is preparing to “bankroll a late-stage trial of Moderna’s mRNA pandemic bird flu vaccine.” H5N1 is spreading across the US ahead of the November presidential elections, and some prominent doctors have already warned about university labs experimenting with H5N1 gain-of-function. 

Sources familiar with the talks between Moderna and the government’s Biomedical Advanced Research and Development Authority, known as Barda, say federal funding could be allocated to the pharma company as early as next month. 

“It is expected to total several tens of millions of dollars, and could be accompanied by a commitment to procure doses if the phase-three trials are successful,” they said.

Moderna has previously said it was trialing H5N1 flu vaccines, with interim data expected soon. 

Moderna is currently testing an H5N1 vaccine, from the 2.3.4.4b subset of viruses, in people. That trial began last summer.

But the trial’s listing in the Clinicaltrials.gov database is cagey about the dosages Moderna is testing, calling them simply dose number 1, 2 and 3. -Statnews

As of Wednesday, the US Department of Agriculture has detected 67 dairy cow herds with H5N1 infections in nine states: Texas, Kansas, New Mexico, Michigan, Idaho, North Carolina, South Dakota, Ohio, and Colorado. 

The ongoing outbreak is linked to dairy cattle. Only two H5N1 cases have been detected among humans. The first was in April, with a Texas dairy worker, and the second was from a Michigan dairy farm last week. Both had mild infections and have since recovered.

FT also said the federal government is in talks with Pfizer about an mRNA vaccine targeting H5N1. 

Keep reading

American oncologists take money from pharmaceutical companies for pure greed

Imagine if your car mechanic took $10,000 a year from Michelin tyres for “consulting” and then tended to recommend their tyres over Pirelli – even if the latter are on sale or better quality or both.

Imagine if your Governor took campaign contributions from Panera bread and then strangely exempted Panera bread from the new minimum wage law.

Imagine if your cancer doctor took money from Karyopharm and then prescribed the toxic poison selenexor (studied in the unethical trial Boston) over safer and cheaper alternatives.

To my knowledge, the first example didn’t happen. The second example is why people think Politicians are sleazy, and the last example is the norm in medicine.

Each year, cancer doctors – particularly academic doctors – take tens of millions in pharma payments while simultaneously writing guidelines that mandate the use of these drugs and simultaneously prescribing them to desperate sick patients who want an objective opinion, but get a biased one instead.

85% of National Comprehensive Cancer Network guidelines writers take pharma payments, and professional organisations are awash in Pharma cash. The American Society of Clinical Oncology (“ASCO”) – our annual meeting – is less about the objective appraisal of science and more a marketing conference for Pharma.

I don’t want to rehash the data showing taking money from Pharma is associated with greater, inappropriate, off-label prescribing, hype, spin and editorials favourable to the sponsor. There is a lot of literature there, and I have written about it extensively. Here, I want to address three things doctors who take personal payments say in rebuttal.

Keep reading

Measles vaccine math

Executive summary

One person has died from measles in the last 10 years. Is this a sign that everyone who has not been infected or vaccinated for measles should get vaccinated?

According to all health authorities the answer is yes.

According to your friendly neighborhood misinformation superspreader (me), the answer is a big NO.

Why? Because you’re more likely to die or be seriously injured for life from these shots than benefit from them.

Here’s how the math works out today

Today, the math is obvious: even if the vaccine is 100% effective, we’d save 1 life every 10 years. But in 10 years, injecting 3M kids a year, even with a 1 in 1M death rate from the vaccine (which would be unbelievably safe), we’d have 30 deaths from the vaccine and 1 from the disease. So it’s a no-brainer today to avoid the shots. The same argument can be made for morbidity since if we just look at autism alone, there’s no question. But “science” isn’t able to make this very obvious association and none of the scientists are willing to be publicly challenged.

The math will be different 70 years from now. Should you get it then?

Let’s look at another scenario. Suppose we stop vaccinating kids tomorrow. Then in around 70 years, most everyone will be unvaccinated and we’ll probably have more measles deaths because the NIH will still never let people know about any early treatment with repurposed drugs.

So we should end up with somewhere around 450 deaths a year which is what it was before we had a measles vaccine.

So you have roughly a 1 in a million chance of dying from the measles each year, but your probability of dying from the shot, assuming it is AMAZINGLY safe at 1 death per million, is about the same. It’s a wash.

Generally, you only want to risk a medical intervention when you are absolutely certain that the benefits way outweigh the risks.

Keep reading

Despite progress in data transparency, the FDA still keeps its data secret

History shows that hiding clinical trial data can be deadly.

Vioxx is a well-known example of how the US drug regulator withheld important information about the harms of the drug for over three years, before it was withdrawn from the market and tens of thousands of people died as a consequence.

Numerous initiatives have been launched over the past two decades to improve access to trial data after it became evident that what was reported in peer-reviewed journals was often cherry-picked and misleading.

Eminent scientists have succeeded in gaining access to trial data from the European and Canadian drug regulators, but a recent analysis published in the Journal of Law, Medicine, & Ethics, found that the US FDA still lags behind others when it comes to data transparency.

Keep reading

VENOM NATION: Shocking Number of Americans Have Tried Gila Monster Venom-Based Weight Loss Drugs

A new poll reveals that a shocking percentage of Americans are taking risky Gila monster venom-based weight loss drugs.

According to the latest KFF Health Tracking Poll, one out of every eight adults in the U.S. has used one of the trendy GLP-1 agonist weight loss and diabetes drugs, such as Ozempic and Wegovy.

This class of drugs is based on compounds in the venom of Gila monsters, a type of small Southwestern lizard that happens to be the only venomous type of lizard found in America. Researchers discovered in the early 1990s that they have a special hormone in their venom that can control hunger and slow digestion.

GLP-1 agonists work by imitating a hormone known as GLP-1 that is naturally produced by the body and secreted from the small intestine to trigger the release of insulin while slowing stomach emptying and blocking glucagon secretion. It can also help people feel fuller after eating by impacting the parts of the brain responsible for processing satiety and hunger signals.

The poll found that roughly 6% of all American adults are currently taking one of these medications, which amounts to 15 million people.

Keep reading

MMR Jabs contain massive Endotoxin

Dear Reader, have you found any measurements of Endotoxin in MMR Jabs?

I have been hunting for a while and will add any data you send me to the following finds. Measured Endotoxin in any type of jab is also of great interest.

In a recent post Steve Kirsch showed that Autism was most commonly associated with MMR Jabs.1 I have shown that jabbing the mother with Endotoxin causes Autism in the unborn child, if it survives.2 Look out for MMRV jabs as well.

Now turning my attention to Autism and other damage done to Children from their jabs, starting with MMR.

Keep reading

KA-CHING! Big Pharma Stocks Soar as They Plan Next Vaccine to Solve Bird Flu Pandemic

Major pharmaceuticals had a fantastic week in the global markets amid speculation that they may be ready to develop a vaccine to treat bird flu.

As fears grow around the world over the risk of another pandemic following the detection of avian bird flu in humans, pharmaceutical companies are benefitting from talk that they may be ready to develop another vaccine to stop another pandemic in its tracks.

The Motley Fool reports:

Shares of vaccine stocks Moderna, Novavax, and BioNTech SE rallied this week, appreciating 23.4%, 16.4%, and 9.3%, respectively, through Thursday trading, according to data from S&P Global Market Intelligence.

While these three stocks gained notoriety back in 2020 during the COVID-19 pandemic, it appears this week’s detection of avian bird flu in a second U.S. citizen and the first-ever detection of avian flu in a human in Australia are spurring fears of an outbreak and thus a possible boon for companies that can quickly produce a bird flu vaccine.

A new avian flu, H5N1, was detected in cattle back in March, with one worker in Texas coming down with associated conjunctivitis at that time. But on Wednesday this week, a second U.S. dairy worker in Michigan tested positive for the avian flu as well. That same day, an Australian dairy worker also tested positive for avian flu, marking the first-ever human case of avian flu in that country.

The discoveries spurred fears of an outbreak. That same day, the Assistant Secretary of Preparedness and Response at the Department of Health and Human Services, Dawn O’Connell, noted that Moderna and Pfizer, which partnered with BioNTech on the COVID-19 mRNA vaccine, were in talks over a potential mRNA vaccine program for the new avian flu.

As has been extensively reported by The Gateway Pundit, major pharmaceuticals including Pfizer, Moderna and AstraZeneca made billions in profits for their shareholders after developing a series of vaccines intended to treat COVID-19.

Keep reading

Further Ethical Concerns on a Recent Self-Amplifying RNA Vaccine Study

I called for the ongoing study to be ceased given the mass safety signal pointed out by The McCullough Foundation.

Today, I outline further ethical flaws:

  1. Informed Consent:
  • Participants must be fully informed about the novel nature of srRNA technology, including potential unknown long-term effects. Ensuring that informed consent is genuinely informed is critical.
  • Detailed information about the potential risks and benefits, including those observed in preclinical and early-phase clinical trials, should be provided.
  • Since the long-term risks are unknown, this seems impossible.
  1. Conflict of Interest:
  • The authors are employees of Replicate Bioscience Inc., which raises concerns about bias. The review should disclose how the conflict of interest was managed.
  • Independent oversight or review by third-party experts who do not stand to benefit financially from the vaccine should be conducted.
  1. Safety Monitoring:
  • Continuous monitoring for adverse effects is essential, especially given the novel nature of srRNA vectors.
  • Clear protocols for reporting and managing adverse events, including long-term follow-up, and plans to mitigate the ill-health effects of AEs and SAEs, must be transparent and outlined up-front.
  1. Methodological Issues

Cause of Death Determination:

  • Accurate determination of causes of death in clinical trials is crucial. There should be a standardized protocol for post-mortem analysis to ascertain whether deaths are related to the vaccine or underlying conditions. Doctors working for the company determining that the vaccine was not the cause of death is insufficient: it’s a novel vaccine: how do they know they are not confusing deaths from COVID19 with deaths from vaccines? PCR is known to be fraught with errors in this context. How do they know that the vaccine does not interact with COVID19 infection and increase mortality?
  • Independent medical reviews of cause-of-death determinations can mitigate bias.

Manufacturing Quality:

  • The article mentions impurities from poor manufacturing that lead to systemic inflammatory responses. To minimize such risks, strict quality control measures and validation processes should be in place.
  • Detailed documentation and transparency regarding manufacturing practices are essential to ensure reproducibility and safety.

Keep reading

What’s the Difference Between Big Tobacco and Big Pharma?

The psychiatric drug industry and big tobacco share striking similarities in their tactics, particularly when it comes to downplaying the risks associated with their products and targeting vulnerable populations like youth. The psychiatric community has gotten away with pretending it is based in science and medicine to sell its snake oil, while the tobacco industry wasn’t so lucky.

A key difference lies in the government’s stance – while tobacco companies face increasing regulations and warnings, the psychiatric drug industry enjoys substantial government support and promotion despite the existence of black box warnings on many of their medications. Both industries have a history of misleading marketing practices and minimizing potential harms.

Big tobacco companies notoriously concealed evidence linking smoking to lung cancer and other diseases for decades. Similarly, psychiatric drug manufacturers have been accused of selectively publishing favorable trial data and underreporting adverse effects.

Despite black box warnings – the FDA’s strongest safety alert – on many psychiatric medications, big pharma’s marketing often portrays an overly rosy picture. A prime example is antidepressants carrying a black box warning about increased suicidality risk in youth. Yet, these drugs continue to be heavily promoted, with limited emphasis on this severe side effect. Worse yet, antidepressants are not approved for under 18’s and still they are prescribed off-label to the age group in increasing numbers. Atypical antipsychotics like Seroquel and Zyprexa also bear a black box warning about increased mortality risk in elderly dementia patients, but their use in this vulnerable population remains widespread.

Moreover, both industries have targeted youth, securing future customers through early exposure and addiction. Big tobacco’s calculated efforts to market to adolescents are well-documented. Many of us remember getting boxes of candy cigarettes as children. The tips of the candy cigarettes were even painted red to simulate they were lit. Likewise, the psychiatric drug industry has been criticized for driving the dramatic rise in childhood psychiatric diagnoses and medication use, despite limited long-term safety data.

However, a crucial difference emerges in the government’s approach. Tobacco companies face intense scrutiny, with advertising restrictions, graphic health warnings on packaging, and mounting litigation. In contrast, the psychiatric drug industry enjoys considerable government financial support, 10.8 billion in the 2024 budget, and lack of stringent oversight.

Keep reading